These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1072 related articles for article (PubMed ID: 12912945)
21. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406 [TBL] [Abstract][Full Text] [Related]
22. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046 [TBL] [Abstract][Full Text] [Related]
23. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277 [TBL] [Abstract][Full Text] [Related]
24. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998 [TBL] [Abstract][Full Text] [Related]
25. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. Liau JY; Liao SL; Hsiao CH; Lin MC; Chang HC; Kuo KT Hum Pathol; 2014 Mar; 45(3):533-9. PubMed ID: 24440092 [TBL] [Abstract][Full Text] [Related]
26. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965 [TBL] [Abstract][Full Text] [Related]
27. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536 [TBL] [Abstract][Full Text] [Related]
28. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521 [TBL] [Abstract][Full Text] [Related]
29. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125 [TBL] [Abstract][Full Text] [Related]
30. Epigenetic inactivation of RASSF1a in uveal melanoma. Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440 [TBL] [Abstract][Full Text] [Related]
31. Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Ferguson AW; Svoboda-Newman SM; Frank TS Mod Pathol; 1998 Jan; 11(1):11-8. PubMed ID: 9556417 [TBL] [Abstract][Full Text] [Related]
32. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Kang S; Kim JW; Kang GH; Lee S; Park NH; Song YS; Park SY; Kang SB; Lee HP Int J Cancer; 2006 May; 118(9):2168-71. PubMed ID: 16331610 [TBL] [Abstract][Full Text] [Related]
33. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis. Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773 [TBL] [Abstract][Full Text] [Related]
34. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038 [TBL] [Abstract][Full Text] [Related]
35. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas. Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073 [TBL] [Abstract][Full Text] [Related]
36. IGSF4 promoter methylation and expression silencing in human cervical cancer. Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594 [TBL] [Abstract][Full Text] [Related]
37. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer. Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681 [TBL] [Abstract][Full Text] [Related]
38. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413 [TBL] [Abstract][Full Text] [Related]
39. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209 [TBL] [Abstract][Full Text] [Related]
40. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]